Veracyte/$VCYT
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Veracyte
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).
- Ticker
- $VCYT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 755
- Headquarters
- South San Francisco, United States
- Website
- www.veracyte.com
Veracyte Metrics
BasicAdvanced
$4B
35.87
$1.39
1.94
-
Price and volume
Market cap
$4B
Beta
1.94
52-week high
$60.91
52-week low
$29.46
Average daily volume
1.3M
Financial strength
Current ratio
9.162
Quick ratio
8.598
Long term debt to equity
0.025
Total debt to equity
0.029
Interest coverage (TTM)
89,359.00%
Profitability
EBITDA (TTM)
110.191
Gross margin (TTM)
73.76%
Net profit margin (TTM)
20.37%
Operating margin (TTM)
16.49%
Effective tax rate (TTM)
1.32%
Revenue per employee (TTM)
$740,000
Management effectiveness
Return on assets (TTM)
4.09%
Return on equity (TTM)
8.77%
Valuation
Price to earnings (TTM)
35.866
Price to revenue (TTM)
7.063
Price to book
2.89
Price to tangible book (TTM)
7.42
Price to free cash flow (TTM)
23.909
Free cash flow yield (TTM)
4.18%
Free cash flow per share (TTM)
2.092
Growth
Revenue change (TTM)
17.28%
Earnings per share change (TTM)
313.15%
3-year revenue growth (CAGR)
19.58%
10-year revenue growth (CAGR)
26.25%
3-year earnings per share growth (CAGR)
51.07%
10-year earnings per share growth (CAGR)
0.11%
What the Analysts think about Veracyte
Analyst ratings (Buy, Hold, Sell) for Veracyte stock.
Analyst projections of the future price of Veracyte stock.
Bulls say / Bears say
Veracyte’s core tests are still growing quickly: second-quarter testing revenue rose 19%, with Decipher up 20% and Afirma up 18%. Management raised its 2026 revenue outlook, suggesting that this momentum is carrying into the rest of the year. (GlobeNewswire)
New Phase III trial analysis found that Decipher can help identify which intermediate-risk prostate cancer patients are more likely to benefit from adding hormone therapy to radiation. Stronger evidence of clinical value could support wider use of the test in treatment decisions. (GlobeNewswire)
Veracyte is extending its reach beyond its established prostate and thyroid tests: TrueMRD has launched with Medicare coverage, while its UroAmp acquisition adds a urine-based bladder cancer platform. UroAmp is not expected to reach the market until late 2028, so this is a longer-term growth opportunity. (GlobeNewswire, GlobeNewswire)
A change to clinical guidelines has begun to weigh on Decipher testing for low-risk prostate cancer. Management lowered its 2026 volume expectations for that group, showing that guideline changes can affect demand even when higher-risk testing remains strong. (Equibles)
Prosigna’s US launch has not yet secured final Medicare technical review and pricing, and the test is excluded from 2026 guidance. Delayed reimbursement or slow uptake against established competitors could postpone its contribution to revenue. (Investing.com, GenomeWeb)
Research and development expense jumped 81% year on year to $29.4 million in the second quarter, reflecting heavier product and clinical investment. If that spending continues to rise faster than revenue, it could limit the gains from Veracyte’s growing sales. (StockTitan)
Data summarised monthly by Lightyear AI. Last updated on 5 Oct 2026.
Veracyte Financial Performance
Revenues and expenses
Veracyte Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing Veracyte
AllUSDEURGBP
Fund name | Fund size | $VCYT weighting |
|---|---|---|
L&G Artificial Intelligence£AIAG | $2.1B | 1.68% |
L&G Artificial Intelligence$AIAI | $2.1B | 1.68% |
iShares Healthcare Innovation£DRDR | $1.3B | 0.40% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.40% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.40% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.